Version 1
: Received: 4 November 2023 / Approved: 6 November 2023 / Online: 6 November 2023 (07:39:25 CET)
How to cite:
Camili, F.E.; Akis, M.; Adali, E.; Hismiogullari, A.A.; Taskin, M.I.; Guney, G.; Afsar, S. Low Oncostatin M Levels Are Associated with the Pathogenesis of Pcos and Its Metabolic Complications. Preprints2023, 2023110299. https://doi.org/10.20944/preprints202311.0299.v1
Camili, F.E.; Akis, M.; Adali, E.; Hismiogullari, A.A.; Taskin, M.I.; Guney, G.; Afsar, S. Low Oncostatin M Levels Are Associated with the Pathogenesis of Pcos and Its Metabolic Complications. Preprints 2023, 2023110299. https://doi.org/10.20944/preprints202311.0299.v1
Camili, F.E.; Akis, M.; Adali, E.; Hismiogullari, A.A.; Taskin, M.I.; Guney, G.; Afsar, S. Low Oncostatin M Levels Are Associated with the Pathogenesis of Pcos and Its Metabolic Complications. Preprints2023, 2023110299. https://doi.org/10.20944/preprints202311.0299.v1
APA Style
Camili, F.E., Akis, M., Adali, E., Hismiogullari, A.A., Taskin, M.I., Guney, G., & Afsar, S. (2023). Low Oncostatin M Levels Are Associated with the Pathogenesis of Pcos and Its Metabolic Complications. Preprints. https://doi.org/10.20944/preprints202311.0299.v1
Chicago/Turabian Style
Camili, F.E., Gurhan Guney and Selim Afsar. 2023 "Low Oncostatin M Levels Are Associated with the Pathogenesis of Pcos and Its Metabolic Complications" Preprints. https://doi.org/10.20944/preprints202311.0299.v1
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common reproductive and endocrinological disease characterized by ovulatory dysfunction, polycystic ovaries, and hyperandrogenism. Adipokines are believed to contribute to developing PCOS and its accompanying metabolic complications such as dyslipidemia, insulin resistance, and cardiovascular diseases. Oncostatin M (OSM), a novel adipokine, plays a role in oogenesis, lipogenesis, and inflammation and may contribute to PCOS pathogenesis and its related metabolic problems. Methods: In this case-control study, the patients were grouped in a 1:1 ratio into either the PCOS (n = 32) or the control group (n = 32). Blood samples were obtained between the 3rd and 5th days of the menstrual cycle. Serum levels of fasting glucose, insulin, C-reactive protein (CRP), low-density lipoprotein, high-density lipoprotein, triglyceride, white blood cell count, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, total testosterone, prolactin estradiol, and OSM were analyzed. Results: OSM levels were significantly lower, but CRP levels were substantially higher in the PCOS group than in the control group (p = .002, p = .001, respectively). OSM was inversely correlated with total cholesterol, non-high-density lipoprotein cholesterol, fasting glucose, and the luteinizing hormone/follicle-stimulating hormone ratio (ρ = .329, p = .017; ρ = .386, p = .005; ρ = .440, p = .001; ρ = .316, p = .023, respectively). Conversely, there was no correlation between OSM and total testosterone level (ρ = .220; p = .118). In the context of inflammation and metabolic parameters, OSM was inversely correlated with CRP, Homeostatic Model Assessment for Insulin Resistance score (HOMA-IR), and low-density lipoprotein cholesterol (LDL) (ρ = .353, p = .019; ρ = .275, p = .048; ρ = .470, p < .001, respectively). The performance of Oncostatin M for diagnosing PCOS showed 50% sensitivity, 75% specificity, and 63% accuracy (p = .009) in ROC curve analysis. Conclusions: Plasma OSM levels were considerably lower in patients with PCOS than in the control group, and this was inversely correlated with the hormonal and metabolic parameters of PCOS. Thus, OSM may be a novel therapeutic target for PCOS and metabolic complications.
Keywords
Polycystic ovary syndrome; Oncostatin M; CRP; Inflammation
Subject
Medicine and Pharmacology, Reproductive Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
